3.3 0.06 (1.85%) | 04-18 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 4.23 | 1-year : | 4.94 |
Resists | First : | 3.62 | Second : | 4.23 |
Pivot price | 2.67 | |||
Supports | First : | 2.41 | Second : | 1.65 |
MAs | MA(5) : | 3.14 | MA(20) : | 2.51 |
MA(100) : | 1.45 | MA(250) : | 1.54 | |
MACD | MACD : | 0.3 | Signal : | 0.2 |
%K %D | K(14,3) : | 79.4 | D(3) : | 81.3 |
RSI | RSI(14): 74.9 | |||
52-week | High : | 3.62 | Low : | 0.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RZLT ] has closed below upper band by 7.7%. Bollinger Bands are 224% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 3.49 - 3.51 | 3.51 - 3.52 |
Low: | 3.2 - 3.22 | 3.22 - 3.23 |
Close: | 3.27 - 3.3 | 3.3 - 3.32 |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Thu, 18 Apr 2024
Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT) - MarketBeat
Fri, 12 Apr 2024
With Rezolute Up 13%, Insider Buyers Count Their Returns - Simply Wall St
Tue, 09 Apr 2024
Rezolute (NASDAQ:RZLT) Coverage Initiated at Maxim Group - MarketBeat
Tue, 19 Mar 2024
Rezolute CFO Daron Evans buys $33.8k in company shares - Investing.com
Tue, 19 Mar 2024
Handok Inc. director buys Rezolute shares worth $17 million - Investing.com
Mon, 18 Mar 2024
Rezolute's chief medical officer buys $18.8k in company stock - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 40 (M) |
Shares Float | 22 (M) |
Held by Insiders | 20.4 (%) |
Held by Institutions | 77.7 (%) |
Shares Short | 252 (K) |
Shares Short P.Month | 1,820 (K) |
EPS | -1.11 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.31 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -31 % |
Return on Equity (ttm) | -48.8 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.58 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -53 (M) |
Levered Free Cash Flow | -33 (M) |
PE Ratio | -3 |
PEG Ratio | 0 |
Price to Book value | 1.42 |
Price to Sales | 0 |
Price to Cash Flow | -2.47 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |